Table 2.

Correlation of the expression of the SHH signaling molecules SHH, PTCH, SMO, and GLI1, as well as p-STAT3 with clinicopathological features in PTC

		SHH				PTCH					SMO			GLI1				p-STAT3
	Total	-	+	++	+++	-	+	++	+++	-	+	++	+++	-	+	++	+++	-	+	++	+++
Gender
Female	121	34	40	33	14	42	39	31	9	37	39	32	13	41	43	31	6	47	47	26	1
Male	43	15	18	8	2	17	15	8	3	14	17	9	3	18	12	10	3	24	10	6	3
Age
≤ 45	87	25	32	21	9	30	28	22	7	27	29	22	9	29	32	24	2	41	26	17	3
> 45	77	24	26	20	7	29	26	17	5	24	27	19	7	30	23	17	7	30	31	15	1
Tumor Size
≤ 2 cm	84	31	29	16	8	41	24	14	5	37	25	15	7	38	22	20	4	39	29	14	2
> 2 cm	80	18	29	25	8	18	30	25	7	14	31	26	9	21	33	21	5	32	28	18	2
ETE
Yes	19	4	7	8	0	2	5	9	3	2	6	8	3	2	11	5	1	4	7	6	2
No	145	45	51	33	16	57	49	30	9	49	50	33	13	57	44	36	8	67	50	26	2
LNM
Yes	98	13	52	24	9	25	36	29	8	16	42	30	10	18	47	29	4	30	41	23	4
No	66	36	6	17	7	34	18	10	4	35	14	11	6	41	8	12	5	41	16	9	0
TNM Stage
I+II	112	39	32	28	13	48	42	17	5	41	43	23	5	46	33	27	6	57	34	18	3
III+IV	52	10	26	13	3	11	12	22	7	10	13	18	11	13	22	14	4	14	23	14	1

ETE, extra thyroidal extension; LNM, lymph node metastasis.